THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

HUTH, Andreas, et al.

Serial No.

09/831,506 V

Filed

14 September 2001

Title: ANTHRANILIC ACID AMIDES AND THEIR USE AS PHARMACEUTICAL AGENTS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.		
	Copies of materials listed but not attached were cited in parent application Serial No.	
	-	
•	Copies of materials listed but not attached were cited in an International Search Report dated 8 May 2000; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed 5 October 2001.	
	Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.	
	Also included are the pending U.S. applications listed below, copies of which are attached:	
FEES	•	
	No fee is required for this Information Disclosure Statement because:	
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;	
	This Information Disclosure Statement is being filed before the mailing of a first action on the merits;	
	This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.	
	A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a	

	notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).		
	A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.		
CERTIFICATION			
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.		
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.		
DEPOSIT ACCOUNT			
If appropriate, attached is a check in the amount of \$ However, the Commissioner is			
hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to			
facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are			
attached for this purpose.			
	Respectfully submitted,		
	Jennifer Branigan Registration No.40,921 Patent Agent		
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410			

Date: 31 October 2001 Jjb:K:\Sch\1806\IDS.PCT.doc